Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ambulero Inc., a biotechnology company (“Ambulero” or the “Company”) developing new cell and gene therapy treatments for patients suffering from severe...

Ambulero Raises Up To $5.5 Million from Orphinic Scientific MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it...